All News
The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis
In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials.
Read Article
🩸 Hb levels markers of RA activity and structural progression? Boston BRASS registry: 1500+ patients.
Low hb at headline associated w/ MTX TNFi and ⬆️ increase in TSS.
Not that surprising provided low Hb is a marker of systemic inflammation. #Abtr0786 #ACR21 @Rheumnow https://t.co/eQLGxsANkk
Aurelie Najm AurelieRheumo ( View Tweet)
Abst0907 #ACR21 @RheumNow observation of GLAS cohort of nrAxSpA pts over 6 yrs showed ~10% of pts progress to AS every 2 years. Specifically after two, four and six years, 8/79 (10.1%), 4/48 (8.3%) and 3/24 (12.5%) nr-axSpA patients progressed to AS. https://t.co/hVpNz1kEgE
Olga Petryna DrPetryna ( View Tweet)
Can RA be cured?
Dr. Thomas' proof of concept RA immunotherapy study: DEN-181 is a liposome immunotherapy given by SQ injx; it's presented by LN-DCs causing: CTL exhaustion while controlling autoreactive CD4+ T cells #ACRbest @rheumnow #ACR21
Abst#0967should have been a plenary! https://t.co/6ZzDgavafS
TheDaoIndex KDAO2011 ( View Tweet)
Does #RA treatment affect low Hb levels? Is there a relationship between Hb and radiographic progression?
#ACR21 Abs#0787
👉🏼Sustained improvements in Hb when treated with bio/non-bio DMARDs
👉🏼Low Hb assoc with incr radiographic progression
@RheumNow
https://t.co/DWgoiqYfAt https://t.co/aSRCT2vGjW
Mrinalini Dey DrMiniDey ( View Tweet)
Prospective multicenter Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Study evaluated 240 patients with axSpA
⭐️Imaging of the SIJ and spine DOES NOT differ in Ps axSpA or axSpA associated with iritis or colitis
Abst# 0902 #ACR21 #ACRBest @RheumNow https://t.co/Y2bRlysXI5
swethaann23 swethaann23 ( View Tweet)
Dr Exarchou presents incidence of PsA in Sweden. 22/100000. 75% received DMARDs within 2 years, which seems high, so perhaps this is tip of iceberg with milder cases undiagnosed. Abstr#0571 #ACR21 @RheumNow https://t.co/kANG6KBnOd
Richard Conway RichardPAConway ( View Tweet)
@KronzerMD @jeffsparks on association of respiratory diseases with incident RA. Upper airway diseases (sinusitis, pharyngitis) seem to associate even more strongly than asthma/COPD. Abstr#564 #ACR21 @RheumNow https://t.co/HvoBOs3OOF
Richard Conway RichardPAConway ( View Tweet)
The rate of progression of nr-axSpA to AS is ~10% every 2 years. Study of 79 patients over 6 years, radiographic progression was 10.1% after 2 years (8/79), 8.3% between 2-4 years (4/48), and 12.5% between 4-6 years (3/24) @RheumNow #ACR21 Abst#0907 https://t.co/hOhpngANIl https://t.co/PiKDgiTES2
Dr. Antoni Chan synovialjoints ( View Tweet)
@SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes (see below). Abstr#952 #ACR21 @RheumNow #ACRBest https://t.co/0lw1QhuJct
Richard Conway RichardPAConway ( View Tweet)
Novel study exploring microbial differences in MZ twins discordant for psoriatic disease
⭐️Ruminococcus 🔽/❎ Gut of Ps pts and maybe associated with Ps Dis
⭐️NL skin scalp of Psoriatic pts 🔽 microbial diversity compared to unaffected twins
Abst#0944 #ACR21 #ACRBest @RheumNow
swethaann23 swethaann23 ( View Tweet)
Dr Manasson presents on microbiome differences between monozygotic twins discordant for psoriatic disease. Differences seen in gut (Ruminococcus virtually absent in psoriatic) and scalp non-lesional skin microbiomes Abstr#0944 #ACR21 @RheumNow https://t.co/8Ch0M4dwUH
Richard Conway RichardPAConway ( View Tweet)
Interim analysis of real world data on AQUILA (Dr Uta Kiltz et al): how gender affects SEC tx and retention rates:
🔷Improvement in BASDAI, PGA, global fnxn & depressive mood - similar in both ♂️&♀️
🔷High SEC retention rates irrespective of gender
@RheumNow #ACR21 abs909 https://t.co/rXa6ELXDJo
sheila RHEUMarampa ( View Tweet)
Dr Mahajan on lung disease in early RA. Common, airway disease in 60%, parenchymal disease in 30%. But minimal/no progression over 1 year which is reassuring. Abstr#574 #ACR21 @RheumNow https://t.co/s9r06MSStF
Richard Conway RichardPAConway ( View Tweet)
So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COVID-19 risks they face.
Thanks @SattuiSEMD @RichardPAConway @EBRheum in particular for driving forward this badly needed work!
#ACR21 ABST0952 @RheumNow https://t.co/L7XS9OblxI https://t.co/LYxR1WUlhM
David Liew drdavidliew ( View Tweet)
Dr. P Crow #PhilipHenchLecture: from LE cell to IFN:
LE cell definition:
👉substance in plasma
👉nuclear material from WBCs altered by the plasma factor
👉active phagocytic cells engulf the altered material #ACR21 @rheumnow https://t.co/jE9wnct6lP
TheDaoIndex KDAO2011 ( View Tweet)
Jorge Plutzky giving a cardiologist perspective at #ACR21. "We've gone from lower is better, to lowest is best" on LDL lowering. PCSK9 inhibitors have changed the game.
@rheumnow https://t.co/oaBE99beSA
Eric Dein ericdeinmd ( View Tweet)
MUC5B and RA-ILD. Dr McDermott @jeffsparks show that MUC5B is associated with RA-ILD, older age at RA diagnosis, and ILD within 5 years of RA onset. Is this a different disease to other RA or modulation by the promotor variant? Abstr#0576 #ACR21 @RheumNow https://t.co/r2fQqxVY6N
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Interesting study by @DrPoddubnyy et al. looking into the efficacy of SEC on HLAB27 subtypes (post hoc analysis of SKIPPAIN trial)
➡ SEC effective for both HLAB27+ and - grps
➡ Significant response seen among HLAB27+ and HLAB27 homozygous pts
@RheumNow #ACR21 abs0917 https://t.co/St37kdGY65
sheila RHEUMarampa ( View Tweet)